MARY OSBAKKEN, M.D.
Osteopathic Medicine at Walnut Ln, Philadelphia, PA
License number
Pennsylvania MD018218E
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
29 W Walnut Ln, Philadelphia, PA 19144
Phone
(215) 844-5067
Personal information
See more information about MARY OSBAKKEN at radaris.comName
Address
Phone
29 W Walnut Ln, Philadelphia, PA 19144
1851 Blue Mountain Pkwy, Harrisburg, PA 17112
29 Walnut Ln, Philadelphia, PA 19144
29 Walnut St, Philadelphia, PA 19144
Professional information
See more information about MARY OSBAKKEN at trustoria.com
Chief Medical Officer At Somnus Therapeutics
Chief Medical Officer At Somnus Therapeutics
Position:
Chief Medical Officer at Somnus Therapeutics, Owner at Osbakken Consulting, LLC
Location:
Greater Philadelphia Area
Industry:
Pharmaceuticals
Work:
Somnus Therapeutics
since Sep 2007
-
Chief Medical Officer
Osbakken Consulting, LLC
since Mar 2007
-
Owner
Follica, Inc
Jan 2009 - Jul 2012
-
Chief Medical Officer
Inotek
Feb 2005 - May 2007
-
Chief Medical Officer
Aventis
2000 - 2005
-
VP, CV, PR Licensing, PR Global Clinical Development, PR-Protocol REveiw COmmittee
Sanofi-Aventis
2000 - 2005
-
VP- Product Realization
University of Pennsylvania
1993 - 2003
-
Adjunct Professor
Bristol-Myers Squibb
1993 - 1999
-
Director of Clinical Development
Education:
University of Illinois at Urbana-Champaign 1961 - 1966
Dr. Mary D Osbakken, Philadelphia PA - MD (Doctor of Medicine)
Dr. Mary D Osbakken, Philadelphia PA - MD (Doctor of Medicine)
Specialties:
Cardiology
Address:
29 W Walnut Ln, Philadelphia 19144
Languages:
English
Education:
Medical School
Temple University
Graduated: 1975
Temple University
Graduated: 1975
Methods For Treating Baldness And Promoting Hair Growth
Methods For Treating Baldness And Promoting Hair Growth
US Patent:
2014007, Mar 20, 2014
Filed:
Dec 6, 2011
Appl. No.:
13/991874
Inventors:
Shikha P. Barman - Bedford MA, US
William D. Ju - Mendham NJ, US
Scott C. Kellogg - Mattapoisett MA, US
Stephen M. Prouty - Doylestown PA, US
Eric Schweiger - New York NY, US
Seth Lederman - New York NY, US
Mary Osbakken - Philadelphia PA, US
Alan D. Schinazi - Providence RI, US
William D. Ju - Mendham NJ, US
Scott C. Kellogg - Mattapoisett MA, US
Stephen M. Prouty - Doylestown PA, US
Eric Schweiger - New York NY, US
Seth Lederman - New York NY, US
Mary Osbakken - Philadelphia PA, US
Alan D. Schinazi - Providence RI, US
International Classification:
A61M 37/00, A61K 38/48
US Classification:
424 9467, 604 22
Abstract:
The invention relates to methods of treating baldness, treating alopecia, promoting hair growth, and/or promoting hair follicle development and/or activation or stimulation on an area of the skin of a subject (for example, a human) by subjecting said area of the skin to integumental perturbation. Integumental perturbation can be used in combination with other treatments for promoting hair growth. The invention provides devices for integumental perturbation for promoting hair growth, and provides pharmaceutical compositions for use in combination with integumental perturbation for promoting hair growth.
Method Of Treating Insomnia
Method Of Treating Insomnia
US Patent:
2012003, Feb 16, 2012
Filed:
Dec 15, 2009
Appl. No.:
13/139881
Inventors:
Gary Cupit - Basking Ridge NJ, US
Anne McCormick - Madison NJ, US
Mary Osbakken - Philadelphia PA, US
Christine Blumhardt - Strafford PA, US
Anne McCormick - Madison NJ, US
Mary Osbakken - Philadelphia PA, US
Christine Blumhardt - Strafford PA, US
Assignee:
SOMNUS THERAPEUTICS, INC. - Bedminster NJ
International Classification:
A61K 31/519, A61P 25/20, A61K 9/00
US Classification:
424400, 5142593
Abstract:
A method of treating insomnia comprising administering to a subject a formulation including zaleplon, wherein the formulation is adapted to release the zaleplon after a lag time of at least about one hour after administration of the formulation, and during which substantially no drug substance is released; provide a time of peak plasma concentration of about 3 hours to about 6 hours after administration; provide an elimination half-life after the time of peak plasma concentration of about 0.5 hours to about 0.3 hours; and provide an area under the curve of about 70 ng·h/mL to about 90 ng·h/mL.